Featured Videos

ORLANDO, FL USA (UroToday.com) - Men with low-risk prostate cancer are increasingly offered the option of active surveillance, involving serial prostate biopsy in order to assess for progression of disease. While the definition of “low-risk” remains controversial, all of the established criteria for active surveillance eligibility are based on template 12-core biopsy of the prostate. This approach is widely adopted, but may be problematic as nearly one-third of all men on active surveillance harbor more aggressive disease as found on final pathology than predicted by 12-core biopsy. Multiparametric MRI-ultrasound fusion-targeted biopsy has been demonstrated to detect higher grade cancer than 12-core biopsy in multiple studies, but has not been studied in the context of active surveillance. In order to evaluate the performance of targeted biopsy and MP-MRI in monitoring for disease progression, Dr. Annerleim Walton-Diaz and colleagues at the National Cancer Institute conducted a study of men with very low-risk disease who underwent serial imaging and biopsy, representing the largest series of its type to date.

auaPatients who met the Epstein criteria for active surveillance underwent an initial MP-MRI with fusion biopsy and 12-core biopsy, and thereafter were followed with a yearly MP-MRI and biopsy session. The study endpoint was progression to a Gleason sum of 3+4 in any core of a targeted or 12-core biopsy. A change in MP-MRI findings, including an increase in lesion diameter, number of lesions, or lesion suspicion score was used as a metric to assess the predictive power of MRI for increase in tumor grade. Over a median follow-up of 18 months, 10 of the 53 patients in the cohort progressed to Gleason 3+4 disease. The majority of this pathologic progression was detected by targeted biopsy. While the positive predictive value of MRI for an increase in Gleason score was 50%, the negative predictive value was high at 84%. Sensitivity and specificity were comparable at 70% and 72% respectively.

These findings may demonstrate that patients with very low-risk prostate cancer can be safely followed with serial MP-MRI if imaging findings remain stable. Where biopsy is indicated, MRI-targeted biopsy detects a majority of progression. As such, MP-MRI and fusion biopsy may be useful as adjuncts or replacements for template 12-core biopsy, specifically in the follow-up of men on active surveillance. Further studies are necessary to delineate the indications, eligibility criteria, and interval of follow-up for introducing these modalities into clinical practice.

Click HERE to listen to the presentation by Annerleim Walton-Diaz, MD

Click HERE to view the presenter's slides from this session

Presented by Annerleim Walton-Diaz at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

National Cancer Institute (NCI), Bethesda, MD USA

Written by Nabeel A. Shakir and Zhamshid Okhunov, University of California (Irvine), and medical writers for UroToday.com

 

 

 

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe